AU2006326506B9 - Demethylpenclomedine analogs and their use as anticancer agents - Google Patents

Demethylpenclomedine analogs and their use as anticancer agents Download PDF

Info

Publication number
AU2006326506B9
AU2006326506B9 AU2006326506A AU2006326506A AU2006326506B9 AU 2006326506 B9 AU2006326506 B9 AU 2006326506B9 AU 2006326506 A AU2006326506 A AU 2006326506A AU 2006326506 A AU2006326506 A AU 2006326506A AU 2006326506 B9 AU2006326506 B9 AU 2006326506B9
Authority
AU
Australia
Prior art keywords
compound
optionally substituted
cancer
pen
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006326506A
Other languages
English (en)
Other versions
AU2006326506A2 (en
AU2006326506B2 (en
AU2006326506A1 (en
Inventor
Lee Roy Morgan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dekk Tek Inc
Original Assignee
Dekk Tek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dekk Tek Inc filed Critical Dekk Tek Inc
Publication of AU2006326506A1 publication Critical patent/AU2006326506A1/en
Publication of AU2006326506A2 publication Critical patent/AU2006326506A2/en
Application granted granted Critical
Publication of AU2006326506B2 publication Critical patent/AU2006326506B2/en
Publication of AU2006326506B9 publication Critical patent/AU2006326506B9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2006326506A 2005-12-13 2006-12-12 Demethylpenclomedine analogs and their use as anticancer agents Active AU2006326506B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75021105P 2005-12-13 2005-12-13
US60/750,211 2005-12-13
PCT/US2006/047526 WO2007070568A2 (en) 2005-12-13 2006-12-12 Demethylpenclomedine analogs and their use as anticancer agents

Publications (4)

Publication Number Publication Date
AU2006326506A1 AU2006326506A1 (en) 2007-06-21
AU2006326506A2 AU2006326506A2 (en) 2008-07-31
AU2006326506B2 AU2006326506B2 (en) 2012-05-17
AU2006326506B9 true AU2006326506B9 (en) 2012-11-15

Family

ID=38163494

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006326506A Active AU2006326506B9 (en) 2005-12-13 2006-12-12 Demethylpenclomedine analogs and their use as anticancer agents

Country Status (6)

Country Link
US (5) US8124596B2 (https=)
EP (1) EP1981850B1 (https=)
JP (1) JP5324921B2 (https=)
AU (1) AU2006326506B9 (https=)
CA (1) CA2632618C (https=)
WO (1) WO2007070568A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1578341A2 (en) 2000-10-11 2005-09-28 Tularik Inc. Modulation of ccr4 function
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
WO2018187414A1 (en) * 2017-04-05 2018-10-11 The Regents Of The University Of California Inhibitors of mtor-rictor interactions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043010A1 (en) * 1999-01-21 2000-07-27 Southern Research Institute Acyl derivatives of 4-demethylpenclomedine, use thereof and preparation thereof
WO2000043009A1 (en) * 1999-01-21 2000-07-27 Southern Research Institute Pyridine compounds, use and preparation thereof
WO2006083930A2 (en) * 2005-02-01 2006-08-10 Southern Research Institute Derivatives of 4-demethylpenclomedine, use thereof and preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4717726A (en) 1986-09-10 1988-01-05 The Dow Chemical Company 3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine having anti-tumor activity
US6235761B1 (en) 1996-06-03 2001-05-22 Neil Hartman Compound, composition and method for treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043010A1 (en) * 1999-01-21 2000-07-27 Southern Research Institute Acyl derivatives of 4-demethylpenclomedine, use thereof and preparation thereof
WO2000043009A1 (en) * 1999-01-21 2000-07-27 Southern Research Institute Pyridine compounds, use and preparation thereof
WO2006083930A2 (en) * 2005-02-01 2006-08-10 Southern Research Institute Derivatives of 4-demethylpenclomedine, use thereof and preparation thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STRUCK, R. ET AL. Cancer Chemotherapy and Pharmacology (2001), 48(1), 47-52 *
TIWARI ET AL. J. Med. Chem. (2002), 45(5), 1079-1085 *

Also Published As

Publication number Publication date
US9422241B2 (en) 2016-08-23
EP1981850B1 (en) 2017-03-22
WO2007070568A3 (en) 2007-11-08
JP5324921B2 (ja) 2013-10-23
US9884051B2 (en) 2018-02-06
US8124596B2 (en) 2012-02-28
WO2007070568A2 (en) 2007-06-21
US20090197844A1 (en) 2009-08-06
AU2006326506A2 (en) 2008-07-31
CA2632618C (en) 2014-04-22
US20200375964A1 (en) 2020-12-03
US20120177634A1 (en) 2012-07-12
AU2006326506B2 (en) 2012-05-17
JP2009519344A (ja) 2009-05-14
CA2632618A1 (en) 2007-06-21
AU2006326506A1 (en) 2007-06-21
US20160354354A1 (en) 2016-12-08
US20180117022A1 (en) 2018-05-03
EP1981850A2 (en) 2008-10-22
US10772878B2 (en) 2020-09-15

Similar Documents

Publication Publication Date Title
JP7142578B2 (ja) ペグ化されたカルフィルゾミブ化合物
PT2097381E (pt) Mono-hidrato de 4-[4-({[4-cloro-3-(trifluorometil)- fenil)]-carbamoíl}-amino)-3-fluorofenoxi]-n-metilpiridina- 2-carboxamida
US8106033B2 (en) Composition and methods for the treatment of proliferative diseases
US20200375964A1 (en) Demethylpenclomedine analogs and their use as anti-cancer agents
AU2005299385B2 (en) Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
JP4162994B2 (ja) 諸疾患状態の処置のための薬物に使用する化合物とその製造方法
US9340563B2 (en) Salts of isophosphoramide mustard and analogs thereof
JP4814245B2 (ja) 低酸素選択性抗腫瘍剤としてのスルホニルヒドラジンのリン酸含有プロドラッグ
AU2013350311B2 (en) Omega-3 analogues
ES2348973T3 (es) Derivados aciclicos de 4-desmetilpenclomedina, utilizacion y preparacion de los mismos.
ES2348972T3 (es) Compuestos de piridina, utilizacion y preparacion de los mismos.
CN116546988A (zh) 5α-羟基-6β-[2-(1H-咪唑-4-基)乙基氨基]胆甾烷-3β-醇的前药及包含其的用于癌症治疗的药物组合物
CA3084804A1 (en) Prodrugs activated by reduction in the cytosol

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 JUN 2008

FGA Letters patent sealed or granted (standard patent)
SREP Specification republished